OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
Sector: Services-Commercial Physical & Biological Research
Industry: Biotechnology
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
based on 145.39M shares outstanding
USOmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery.
The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates.
Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets.
The company was founded in 2012 and is based in Emeryville, California.
CAROLYN R. BERTOZZI, Ph.D.
Director; Anne T. and Robert M. Bass Professor of Chemistry
Carolyn Bertozzi, Ph.D.
Chair, Science and Technology Committee
JENNIFER COCHRAN, Ph.D.
Director; Macovski Professor of Bioengineering and Vice President for SLAC National Linear Accelerator Laboratory and for Strategic Initiatives, Stanford University; Member, Science and Technology Committee
Matthew W. Foehr
President, Chief Executive Officer & Director
Employees
89
Country
US
Sector
Healthcare
Website
omniab.com
Loading congressional disclosures…
based on 145.39M shares outstanding
US30d Avg
1.34M
60d Avg
1.97M
90d Avg
1.49M
